Recognizing Co-Pathologies in Alzheimer’s Disease and Dementia with Lewy Bodies
Overview
Recent research highlights that most patients with Alzheimer’s disease (AD) or dementia with Lewy bodies (DLB) exhibit multiple co-pathologies rather than pure pathological forms. The presence of Lewy body co-pathology in AD patients is associated with more rapid cognitive decline, while AD co-pathology in DLB patients correlates with accelerated progression and poorer cognition.
Background
Alzheimer’s disease and dementia with Lewy bodies were first characterized in the early 1900s through clinical and neuropathological observations. Historically, these diseases were considered distinct with pure pathological features, but modern studies using biomarkers and imaging have revealed frequent co-occurrence of multiple pathologies. Understanding these co-pathologies is crucial as they influence clinical presentation, disease progression, and diagnostic accuracy.
Data Highlights
Patient Group
Lewy Body Positivity
AD Biomarker Positivity
Clinical Outcome
AD with LB co-pathology
Positive
Positive
More rapid cognitive decline
AD without LB co-pathology
Negative
Positive
Slower cognitive decline
LB pathology alone
Positive
Negative
Less overall cognitive impairment; focal dysexecutive and visuospatial deficits
AD biomarker negative, LB positive initially diagnosed as AD
Positive
Negative
44% diagnosis revised to other dementia etiology
Key Findings
Most patients with AD or DLB have mixed pathologies rather than pure forms.
Lewy body co-pathology in AD patients leads to faster cognitive decline.
Patients with LB pathology alone show distinct cognitive deficits compared to AD.
High rate of initial misdiagnosis in patients with LB pathology but negative AD biomarkers.
AD co-pathology in DLB and Parkinson’s disease dementia is linked to more rapid progression and poorer cognition.
Imaging and fluid biomarkers enable in vivo detection of co-pathologies, improving diagnostic accuracy.
Clinical Implications
Clinicians should consider the presence of co-pathologies when diagnosing and managing patients with AD and DLB, as these influence disease progression and clinical features. Biomarker and imaging tools such as CSF alpha-synuclein assays and FDG-PET can aid in identifying mixed pathologies, guiding more accurate diagnosis and potentially informing targeted therapeutic strategies.
Conclusion
Recognition of co-pathologies in AD and DLB challenges traditional diagnostic boundaries and underscores the need for multimodal biomarker approaches. This paradigm shift facilitates personalized management and highlights multiple pathological targets for future therapies.
References
Silva-Rodríguez et al. 2024 -- Effects of Lewy-related pathology in Alzheimer’s disease
Duong et al. 2023 -- Metabolic disruptions in AD and Lewy body co-pathology
Colloby et al. 2022 -- Regional neuropathological involvement in AD and DLB
